AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Category: Markets

Published: 2026-06-22T22:36:24.000Z

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.